FindTrial
Sign In

"Letrozole versus hormone replacement therapy for frozen embryo transfer".

"To compare the pregnancy outcomes of letrozole-induced endometrial preparation with hormone replacement therapy for frozen embryo transfer".

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2023/06/053516
Enrollment
50
Registered
2023-06-05
Start date
Unknown
Completion date
Unknown
Last updated
2023-06-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: Z317- Encounter for procreative management and counseling for gestational carrier

Interventions

Intervention1: Letrozole: 5 mg once daily for 5 days from day 2/3 of menses. Control Intervention1: Hormone replacement therapy: Tab Estradiol valerate 2 mg three times a day from day 2/3 of menses.

Sponsors

None
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Women who will be undergoing frozen embryo transfer (FET)

Exclusion criteria

Exclusion criteria: Hydrosalpinx (not clipped or occluded); maternal medical disease; natural or modified natural FET cycles; cycles cancelled due to endometrial polyp, premature progesterone elevation or inadequate uterine blood flow.

Design outcomes

Primary

MeasureTime frame
Biochemical pregnacy rate, clinical pregnancy rate, abortion rateTimepoint: 4 weeks (At the end of ongoing frozen embryo transfer cycle), 8 weeks—

Secondary

MeasureTime frame
Endometrial thickness before transfer (mm). Serum Progesterone on day of transfer.Timepoint: 4 weeks (At the end of ongoing frozen embryo transfer cycle), 8 weeks—

Countries

India

Contacts

Public ContactDr Vandana Mohan

Southend Fertility and IVF, Vasant Vihar

preetyvandana@gmail.com9811775705

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026